-
This pharmaceutical company raised US$120 million to develop innovative treatments for diabetes
Time of Update: 2022-01-10
It is worth mentioning that the first product of Yinnuo Medicine is an innovative diabetes drug-Suparutide (long-acting human GLP-1), which is currently undergoing clinical Phase 3 research.
-
Within 1 week, 7 new drugs of this pharmaceutical company were applied for clinical application and marketing
Time of Update: 2022-01-10
On December 24, the clinical application of Hengrui Medicine's 2 Class 1 new drugs was accepted by CDE, namely SHR-1816 injection and SHR-1501 for injection; in addition, the first company submitted 10% fat emulsion (OO )/5.
-
This pharmaceutical company has completed hundreds of millions of yuan in financing, and it is expected that 2-3 products will be approved for listing each year in the next 3 years
Time of Update: 2022-01-10
As one of the few domestic pharmaceutical companies that have entered the field of respiratory inhalation preparations, Omini has many advantages in preparation R&D and device design.
Many of the company's projects are gradually entering phase III clinical trials, which will bring China's self-developed international-level respiratory preparations to the domestic market .
-
Huadong Medicine: The core commercial subsidiary of the medical aesthetics sector intends to liquidate and cancel
Time of Update: 2022-01-10
Huadong Ningbo was consolidated into a listed company, and Huadong Medicine also started the path of medical beauty layout .
In addition, Huadong Medicine's reply letter pointed out that it plans to enter the statutory liquidation stage after its business expires on December 31 in Ningbo, East China .
-
Pharmaceutical giants report large-scale mergers and acquisitions!
Time of Update: 2022-01-09
For this transaction, if the negotiations are successful, it means that Samsung will join the ranks of global biotech giants and expand its pharmaceutical business to areas other than biosimilars and contract production transactions .
-
This pharmaceutical company has a bumper harvest, and 5 new drug listing applications have been approved during the year
Time of Update: 2022-01-09
On December 28, CStone Pharmaceuticals announced that the company’s gastrointestinal stromal tumor (GIST), the first precision targeted drug of its kind, AYVAKIT (avatinib), has been approved for the new drug listing application in Hong Kong, China, for the treatment of carrier Adult patients with unresectable or metastatic gastrointestinal stromal tumor with PDGFRA D842V mutation .
-
To seize the high value-added track of nucleoside APIs, a well-known pharmaceutical company completes a blockbuster acquisition
Time of Update: 2022-01-09
It is reported that the acquisition of Huachang Hi-Tech by Huadong Medicine will help the company develop a new industrialization platform focusing on nucleoside products, semi-synthetic antiparasitic drugs from microbial sources and other drugs, and further cultivate the field of industrial microbiology .
-
This pharmaceutical company declares the 7th indication for its innovative anti-tumor drug!
Time of Update: 2022-01-09
Recently, Cinda Biotech announced that the National Medical Products Administration (NMPA) has officially accepted the innovative PD-1 inhibitor Daboshu® (sintilimab injection) combined with bevacizumab and chemotherapy for the treatment of transdermal growth factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) treatment failed EGFR gene mutation-positive locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) new indication listing application (sNDA) .
-
This pharmaceutical company invested 100 million to participate in the bankruptcy and reorganization of the industrial microbial giant
Time of Update: 2022-01-09
It is reported that after the Majestic Health Microbial Health Industry Platform, Huachang Hi-Tech will become a new industrialization platform in the company's industrial microbiology field, focusing on the industrialization of nucleoside products, semi-synthetic antiparasitic drugs from microbial sources and other drugs.
-
2022 Shandong International Health Industry Expo Astragalus Product Exhibition
Time of Update: 2022-01-09
DJK Shandong Health Expo, oriented to the global health consumer market, creates an international health industry rapid integration and development platform; Exhibitor recommendation: Chengdu Ximilai Technology Co.
-
Hundreds of billions of Chinese medicine giants plan to expand the medical beauty track
Time of Update: 2022-01-08
It is reported that after the above transfer and capital increase are completed, Yunzhen Company plans to open 8 medical outpatient departments in Beijing and Shanghai by December 2022 to achieve the company's phased strategic intentions .
-
Robotic surgery in Xinjiang enters the era of ultra-precision to achieve "win-win" for doctors and patients
Time of Update: 2022-01-08
Yang Yining, deputy secretary of the Party Committee and Dean of the People's Hospital of the Autonomous Region, said that the promotion and popularization of Da Vinci robotic surgery is of great significance to improve the level of surgical treatment in Xinjiang, enhance the ability to treat difficult and severe cases, and promote the high-quality transformation and development of hospitals .
-
This innovative drug company with a rich R&D pipeline has received more than 600 million yuan in financing!
Time of Update: 2022-01-08
According to data, Xuanzhu Biotechnology was established in 2002, and it is one of the few domestic platform-based innovative drug companies capable of independent research and development in the fields of small molecules and macromolecules at the same time .
-
WHO actively explores next-generation new crown vaccine
Time of Update: 2022-01-07
The Director-General of the World Health Organization Tan Desai said on the 22nd that the world is currently making the most of the available resources of the new crown vaccine to fight the epidemic.
-
300 million yuan!
Time of Update: 2022-01-03
In addition, Blue Sail Medical also chose to invest in OCT (Optical Coherence Tomography) company Nanjing Wolfman in order to further expand the business layout of cardio-cerebrovascular medical equipment and enrich its product portfolio in the field of coronary intervention .
-
Hengrui Medicine will soon apply for another ophthalmic drug
Time of Update: 2022-01-03
At the end of last year, Hengrui Medicine received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration, approving the company's SHR8058 eye drops to carry out clinical trials for dry eye related to meibomian gland dysfunction .
-
Over 200 million US dollars!
Time of Update: 2022-01-03
According to the data, Proton is a customized development and production (CDMO) company for pharmaceuticals.
Proton's API CMO business Realized revenue of 863 million yuan, accounting for 69% of the company's total operating revenue, a year-on-year increase of 29% .
-
Why does a pharmaceutical company acquire a loss-making pharmaceutical factory for more than 200 million yuan?
Time of Update: 2022-01-02
After the acquisition of Taihua Hangzhou by Jiuzhou Pharmaceutical, the company can expand its production capacity and improve production efficiency, and undertake CDMO (medical contract customized research and development and production) business at home and abroad .
-
This pharmaceutical outsourcing company was investigated by more than 230 institutions in one day!
Time of Update: 2022-01-02
Public information shows that Medicilon is a professional biomedicine preclinical comprehensive research and development service CRO, providing a full range of one-stop new drug research and development services that meet domestic and international reporting standards for global pharmaceutical companies and scientific research institutions .
-
Before 2026, this pharmaceutical company plans to list 20 blockbuster drugs
Time of Update: 2022-01-01
It is reported that in order to accelerate the research and development of new drugs in oncology and other fields, GSK's R&D investment in the first three quarters of 2021 will increase by 34% year-on-year .
